Figure 8. Stroke prevention strategy in patients with AF

Slides:

Advertisements

Similar presentations

Apixaban in Patients with Atrial Fibrillation

Advertisements

AF and NOACs An UPDATE JULY 2014

Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target

CHADS 2 -> CHA 2 DS 2 VASc. CHA2DS2-VASc Risk Score CHF or LVEF < 40% 1 Hypertension1 Age > 752 Diabetes1 Stroke/TIA/ Thromboembolism 2 Vascular Disease.

The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. Benefit of Anticoagulation Unlikely in Patients With Atrial.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Does the Left Atrial Appendage Morphology Correlate.

Postulated Association Between AF and Stroke

Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

Fig ACCF/AHA Guideline for the management of heart failure

Difficult situations in anticoagulation after stroke

How Do We Incorporate Patient Perspectives Into Clinical Trial Design?

Antithrombotic Therapy in Atrial Fibrillation

An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.

Frontiers of anticoagulation therapy for atrial fibrillation

No evidence that AF type significantly impacts stroke risk

ELIGIBILITY: MRC/BHF Heart Protection Study

AMIA Joint Summits 2017 San Francisco

The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines Laurent Macle, MD,

Circ Cardiovasc Qual Outcomes

CHA2DS2-VASc Scoring System General AF Treatment Guidance.

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal Gregory.

by Anuj Shah, Anand Shewale, Corey J. Hayes, and Bradley C. Martin

Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.

Role of the CHADS2 Score in Acute Coronary Syndromes

Click here for title Click here for subtitle

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

CHADS2 Score Predicts Postoperative Atrial Fibrillation in Patients Undergoing Elective Pulmonary Lobectomy Svetlana Kotova, MD, Mansen Wang, PhD, Katie.

2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Laurent Macle, MD, John Cairns, MD, Kori.

Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control

Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation Lena Rivard, MD, MSc, Paul Khairy, MD,

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Appropriate Stroke Prevention Strategies in Atrial Fibrillation

Nat. Rev. Cardiol. doi: /nrcardio

Oral Anticoagulants in AFa,b A Brief History.

Selecting NOACs for High-Risk Patients

Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.

CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation Walid Saliba, MD, MPH, Gad Rennert,

Long-Term Risk of Ischemic Stroke After the Cox-Maze III Procedure for Atrial Fibrillation Anders Albåge, MD, PhD, Ulrik Sartipy, MD, PhD, Göran Kennebäck,

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Presenter: Wen-Ching Lan Date: 2018/10/17

The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines Laurent Macle, MD,

Self-Management of Anticoagulant Therapy in Mechanical Heart Valve Patients: A Matched Cohort Study Thomas Decker Christensen, MD, PhD, Flemming Skjøth,

Antithrombotic Therapy for Atrial Fibrillation

CHADS2 Score, Statin Therapy, and Risks of Atrial Fibrillation

Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk? Peter J. Zimetbaum, MD, Amit Thosani, MD, Hsing-Ting Yu, MPH, Yan.

2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Atul Verma, MD, John A. Cairns, MD, L.

Left atrial appendage exclusion: An alternative to anticoagulation in nonvalvular atrial fibrillation Kareem Bedeir, MBChB, MS, David R. Holmes, MD,

Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Efficacy and safety outcomes with NOAC compared with warfarin in NOAC patients with 14 457 years of risk and 49 418 warfarin patients with 75 747.

Optimizing Atrial Fibrillation Management

2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Jason G. Andrade, MD, Atul Verma, MD,

5 Good Minutes on Atrial Fibrillation-related Stroke

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The Euro Heart Survey Maura Marcucci, MD, Gregory Y.H. Lip,

Volume 10, Issue 9, Pages (September 2013)

The American Journal of Medicine

Volume 72, Issue 4, Pages (August 2007)

Adjusted ORs of AF within 30 days after bereavement with specific characteristics versus non-bereaved with the same characteristics. * *The vertical dashed.

Erratum Canadian Journal of Cardiology

Adjusted ORs of AF according to time since bereavement versus non-bereaved in a population from Denmark between 1995 and * *ORs are adjusted for.

Figure 1. Decision-making process of stroke prevention in patients with AF from Asia. The decision-making process includes stroke risk evaluation, OAC.

Gianluigi Savarese et al. JCHF 2016;4:

by Deborah M. Stephens, and John C. Byrd

The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.

Presentation transcript:

Figure 8. Stroke prevention strategy in patients with AF Figure 8. Stroke prevention strategy in patients with AF. AF = atrial fibrillation; HF = heart failure; NOAC = non-vitamin K oral anticoagulant; OAC = oral anticoagulation. *CHA2DS2-VASs score: a congestive HF, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65–74, female. Figure 8. Stroke prevention strategy in patients with AF. AF = atrial fibrillation; HF = heart failure; NOAC = non-vitamin K oral anticoagulant; OAC = oral anticoagulation. *CHA2DS2-VASs score: a congestive HF, hypertension, age ≥75 (doubled), diabetes mellitus, prior… Korean Circ J. 2018 Dec;48(12):1033-1080. https://doi.org/10.4070/kcj.2018.0339